Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2/2015

01-06-2015

Allosteric therapies for lung cancer

Authors: Ye Ling, Meiling Jing, Xiang-dong Wang

Published in: Cancer and Metastasis Reviews | Issue 2/2015

Login to get access

Abstract

Allostery is a regulation at a distance by conveying information from one site to another and an intrinsic property of dynamic proteins. Allostery plays an essential role in receptor trafficking, signal transmission, controlled catalysis, gene turn on/off, or cell apoptosis. Allosteric mutations are considered as one of causes responsible for cancer development, leading to “allosteric diseases” by stabilizing an active or inactive conformation or changing the dynamic distribution of preexisting propagation pathways. The present article mainly focuses on the potential of allosteric therapies for lung cancer. Allosteric drugs may have several advantages over traditional drugs. The epidermal growth factor receptor mutations and signaling pathways downstream (such as PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways) were suggested to play a key role in lung cancer and considered as targets of allosteric therapy. Some allosteric inhibitors for lung cancer-specific targets and a series of preclinical trials of allosteric inhibitors for lung cancer have been developed and reported. We expect that allosteric therapies will gain more attentions to develop combinatorial strategies for lung cancer and metastasis.
Literature
1.
Di Paola, L., & Giuliani, A. (2015). Protein contact network topology: a natural language for allostery. Current Opinion in Structural Biology, 31, 43–48.PubMedCrossRef
2.
Nussinov, R., & Tsai, C. J. (2013). Allostery in disease and in drug discovery. Cell, 153(2), 293–305.PubMedCrossRef
3.
Tsai, C. J., Del Sol, A., & Nussinov, R. (2009). Protein allostery, signal trans- mission and dynamics: a classification scheme of allosteric mechanisms. Molecular Biosystems, 5(3), 207–216.PubMedCentralPubMedCrossRef
4.
Changeux, J. P. (2012). Allostery and the Monod-Wyman-Changeux model after 50 years. Annual Review of Biophysics, 41, 103–133.PubMedCrossRef
5.
Collier, G., & Ortiz, V. (2013). Emerging computational approaches for the study of protein allostery. Archives Biochemistry and Biophysics, 538(1), 6–15.CrossRef
6.
Manley, G., & Loria, J. P. (2012). NMR insights into protein allostery. Archives Biochemistry and Biophysics, 519(2), 223–231.CrossRef
7.
Fenwick, R. B., Esteban-Martín, S., & Salvatella, X. (2014). The ensemble nature of allostery. Nature, 508(7496), 331–339.CrossRef
8.
Strickland, D., Moffat, K., & Sosnick, T. R. (2008). Light-activated DNA binding in a designed allosteric protein. Proceedings of the National Academy of Sciences of the United States of America, 105(31), 10709–10714.PubMedCentralPubMedCrossRef
9.
Csermely, P., Palotai, R., & Nussinov, R. (2010). Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends in Biochemical Sciences, 35(10), 539–546.PubMedCentralPubMedCrossRef
10.
Mittag, T., Kay, L. E., & Forman-Kay, J. D. (2010). Protein dynamics and conformational disorder in molecular recognition. Journal of Molecular Recognition, 23(2), 105–116.PubMed
11.
Nussinov, R., Tsai, C. J., Xin, F., & Radivojac, P. (2012). Allosteric post-translational modification codes. Trends in Biochemical Sciences, 37(10), 447–455.PubMedCrossRef
12.
Ma, B., Tsai, C. J., Haliloğlu, T., & Nussinov, R. (2011). Dynamic allostery: linkers are not merely flexible. Structure, 19(7), 907–917.PubMedCrossRef
13.
del Sol, A., Tsai, C. J., Ma, B., & Nussinov, R. (2009). The origin of allosteric functional modulation: multiple pre-existing pathways. Structure, 17(8), 1042–1050.PubMedCentralPubMedCrossRef
14.
Tsai, C. J., del Sol, A., & Nussinov, R. (2008). Allostery: absence of a change in shape does not imply that allostery is not at play. Journal of Molecular Biology, 378(1), 1–11.PubMedCentralPubMedCrossRef
15.
Boehr, D. D., Nussinov, R., & Wright, P. E. (2009). The role of dynamic conformational ensembles in biomolecular recognition. Nature Chemical Biology, 5(11), 789–796.PubMedCentralPubMedCrossRef
16.
Kar, G., Keskin, O., Gursoy, A., & Nussinov, R. (2010). Allostery and population shift in drug discovery. Current Opinion in Pharmacology, 10(6), 715–722.PubMedCrossRef
17.
Popovych, N., Sun, S., Ebright, R. H., & Kalodimos, C. G. (2006). Dynamically driven protein allostery. Nature Structural & Molecular Biology, 13(9), 831–838.CrossRef
18.
Urwyler, S. (2011). Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacological Reviews, 63(1), 59–126.PubMedCrossRef
19.
De Lean, A., Stadel, J. M., & Lefkowitz, R. J. (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta- adrenergic receptor. Journal of Biological Chemistry, 255(15), 7108–7117.PubMed
20.
Keov, P., Sexton, P. M., & Christopoulos, A. (2011). Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology, 60(1), 24–35.PubMedCrossRef
21.
Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A., Shaw, D. B., Sexton, P. M., & Christopoulos, A. (2010). Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology, 35(4), 855–869.PubMedCentralPubMedCrossRef
22.
Suratman, S., Leach, K., Sexton, P., Felder, C., Loiacono, R., & Christopoulos, A. (2011). Impact of species variability and ‘probe-dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. British Journal of Pharmacology, 162(7), 1659–1670.PubMedCentralPubMedCrossRef
23.
Valant, C., Felder, C. C., Sexton, P. M., & Christopoulos, A. (2012). Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Molecular Pharmacology, 81(1), 41–52.PubMedCrossRef
24.
Gregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J. (2011). Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology, 60(1), 66–81.PubMedCentralPubMedCrossRef
25.
Hall, D. A. (2000). Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Molecular Pharmacology, 58(6), 1412–1423.PubMed
26.
Christopoulos, A., & Kenakin, T. (2002). G protein-coupled receptor allosterism and complexing. Pharmacological Reviews, 54(2), 323–374.PubMedCrossRef
27.
Nussinov, R., Tsai, C. J., & Ma, B. (2013). The underappreciated role of allostery in the cellular network. Annual Review of Biophysics, 42, 169–189.PubMedCrossRef
28.
Tzeng, S. R., & Kalodimos, C. G. (2011). Protein dynamics and allostery: an NMR view. Current Opinion in Structural Biology, 21(1), 62–67.PubMedCrossRef
29.
Popovych, N., Tzeng, S. R., Tonelli, M., Ebright, R. H., & Kalodimos, C. G. (2009). Structural basis for cAMP-mediated allosteric control of the catabolite activator protein. Proceedings of the National Academy of Sciences of the United States of America, 106(17), 6927–6932.PubMedCentralPubMedCrossRef
30.
Tzeng, S. R., & Kalodimos, C. G. (2009). Dynamic activation of an allosteric regulatory protein. Nature, 462(7271), 368–372.PubMedCrossRef
31.
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Evers, B. M. (2012). mTOR inhibitors in cancer therapy. Cancer Letters, 319(1), 1–7.PubMedCrossRef
32.
Goncharova, E. A. (2013). mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB Journal, 27(5), 1796–1807.PubMedCentralPubMedCrossRef
33.
Geserick, C., Meyer, H. A., & Haendler, B. (2005). The role of DNA response elements as allosteric modulators of steroid receptor function. Molecular and Cellular Endocrinology, 236(1-2), 1–7.PubMedCrossRef
34.
Ma, B., Tsai, C. J., Pan, Y., & Nussinov, R. (2010). Why does binding of proteins to DNA or proteins to proteins not necessarily spell function? ACS Chemical Biology, 5(3), 265–272.PubMedCentralPubMedCrossRef
35.
Garcia, H. G., Sanchez, A., Boedicker, J. Q., Osborne, M., Gelles, J., Kondev, J., & Phillips, R. (2012). Operator sequence alters gene expression independently of transcription factor occupancy in bacteria. Cell Reports, 2(1), 150–161.PubMedCentralPubMedCrossRef
36.
Kim, S., Broströmer, E., Xing, D., Jin, J., Chong, S., Ge, H., Wang, S., Gu, C., Yang, L., Gao, Y. Q., Su, X. D., Sun, Y., & Xie, X. S. (2013). Probing allostery through DNA. Science, 339(6121), 816–819.PubMedCentralPubMedCrossRef
37.
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013). Emerging paradigms in GPCR allostery: implications for drug discovery. Nature Reviews Drug Discovery, 12(8), 630–644.PubMedCrossRef
38.
Schelshorn, D., Joly, F., Mutel, S., Hampe, C., Breton, B., Mutel, V., & Lütjens, R. (2012). Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Molecular Pharmacology, 81(3), 309–318.PubMedCrossRef
39.
Foster, A. C., & Kemp, J. A. (2006). Glutamate- and GABA-based CNS therapeutics. Current Opinion in Pharmacology, 6(1), 7–17.PubMedCrossRef
40.
Lindberg, J. S., Culleton, B., Wong, G., Borah, M. F., Clark, R. V., Shapiro, W. B., Roger, S. D., Husserl, F. E., Klassen, P. S., Guo, M. D., Albizem, M. B., & Coburn, J. W. (2005). Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology, 16(3), 800–807.PubMedCrossRef
41.
Lieberman-Blum, S. S., Fung, H. B., & Bandres, J. C. (2008). Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clinical Therapeutics, 30(7), 1228–1250.PubMedCrossRef
42.
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011). Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. Journal of Clinical Investigation, 121(4), 1231–1241.PubMedCentralPubMedCrossRef
43.
Lu, S., Li, S., & Zhang, J. (2014). Harnessing allostery: a novel approach to drug discovery. Medicinal Research Reviews, 34(6), 1242–1285.PubMedCrossRef
44.
Alamgeer, M., Ganju, V., & Watkins, D. N. (2013). Novel therapeutic targets in non-small cell lung cancer. Current Opinion in Pharmacology, 13(3), 394–401.PubMedCrossRef
45.
Li, T., Kung, H. J., Mack, P. C., & Gandara, D. R. (2013). Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. Journal of Clinical Oncology, 31(8), 1039–1049.PubMedCentralPubMedCrossRef
46.
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J. S., Squire, J., Thunnissen, E., & Ladanyi, M. (2013). Molecular testing guideline for Selection of Lung Cancer Patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Molecular Diagnostics, 15(4), 415–453.PubMedCrossRef
47.
Hynes, N. E., & MacDonald, G. (2009). ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology, 21(2), 177–184.PubMedCrossRef
48.
Endres, N. F., Engel, K., Das, R., Kovacs, E., & Kuriyan, J. (2011). Regulation of the catalytic activity of the EGF receptor. Current Opinion in Structural Biology, 21(6), 777–784.PubMedCentralPubMedCrossRef
49.
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell, 125(6), 1137–1149.PubMedCrossRef
50.
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011). Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Molecular Cell, 42(1), 9–22.PubMedCentralPubMedCrossRef
51.
Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009). Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell, 137(7), 1293–1307.PubMedCentralPubMedCrossRef
52.
Papakyriakou, A., Vourloumis, D., Tzortzatou-Stathopoulou, F., & Karpusas, M. (2009). Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation. Proteins, 76(2), 375–386.PubMedCrossRef
53.
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129–2139.PubMedCrossRef
54.
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., & Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497–1500.PubMedCrossRef
55.
Gazdar, A. F. (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 28(S1), S24–S31.PubMedCentralPubMedCrossRef
56.
Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 11(3), 217–227.PubMedCentralPubMedCrossRef
57.
Shan, Y., Eastwood, M. P., Zhang, X., Kim, E. T., Arkhipov, A., Dror, R. O., Jumper, J., Kuriyan, J., & Shaw, D. E. (2012). Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell, 149(4), 860–870.PubMedCrossRef
58.
Dixit, A., & Verkhivker, G. M. (2011). Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Computational Biology, 7(10), e1002179.PubMedCentralPubMedCrossRef
59.
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical Cancer Research, 12(19), 5764–5769.PubMedCrossRef
60.
Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M., & Eck, M. J. (2008). The T790 mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America, 105(6), 2070–2075.PubMedCentralPubMedCrossRef
61.
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008). Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nature Structural & Molecular Biology, 15(10), 1109–1118.CrossRef
62.
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012). Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16(1), 103–119.PubMedCentralPubMedCrossRef
63.
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 8(8), 627–644.PubMedCentralPubMedCrossRef
64.
Britten, C. D. (2013). PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemotherapy and Pharmacology, 71(6), 1395–1409.PubMedCrossRef
65.
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Malaponte, G., Mazzarino, M. C., Nicoletti, F., Libra, M., Maksimovic-Ivanic, D., Mijatovic, S., Montalto, G., Cervello, M., Laidler, P., Milella, M., Tafuri, A., Bonati, A., Evangelisti, C., Cocco, L., Martelli, A. M., & McCubrey, J. A. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget, 2(3), 135–164.PubMedCentralPubMed
66.
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., Candido, S., Libra, M., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Cocco, L., Evangelisti, C., Chiarini, F., & Martelli, A. M. (2012). Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/ mTOR cascades which alter therapy response. Oncotarget, 3(9), 954–987.PubMedCentralPubMed
67.
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., Mazzarino, M. C., Fagone, P., Nicoletti, F., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Chiarini, F., Evangelisti, C., Cocco, L., & Martelli, A. M. (2012). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget, 3(10), 1068–1111.PubMedCentralPubMed
68.
Iida, M., Brand, T. M., Campbell, D. A., Starr, M. M., Luthar, N., Traynor, A. M., & Wheeler, D. L. (2013). Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology & Therapy, 14(6), 481–491.CrossRef
69.
Holland, W. S., Chinn, D. C., Lara, P. N., Jr., Gandara, D. R., & Mack, P. C. (2015). Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. Journal of Cancer Research and Clinical Oncology, 141(4), 615–626.PubMedCrossRef
70.
Gadgeel, S. M., & Wozniak, A. (2013). Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clinical Lung Cancer, 14(4), 322–332.PubMedCrossRef
71.
Soria, J. C., Shepherd, F. A., Douillard, J. Y., Wolf, J., Giaccone, G., Crino, L., Cappuzzo, F., Sharma, S., Gross, S. H., Dimitrijevic, S., Di Scala, L., Gardner, H., Nogova, L., & Papadimitrakopoulou, V. (2009). Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology, 20(10), 1674–1681.PubMedCrossRef
72.
Price, K. A., Azzoli, C. G., Krug, L. M., Pietanza, M. C., Rizvi, N. A., Pao, W., Kris, M. G., Riely, G. J., Heelan, R. T., Arcila, M. E., & Miller, V. A. (2010). Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Journal of Thoracic Oncology, 5(10), 1623–1629.PubMedCentralPubMedCrossRef
73.
Ramalingam, S. S., Owonikoko, T. K., Behera, M., Subramanian, J., Saba, N. F., Kono, S. A., Gal, A. A., Sica, G., Harvey, R. D., Chen, Z., Klass, C. M., Shin, D. M., Fu, H., Sun, S. Y., Govindan, R., & Khuri, F. R. (2013). Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. Journal of Thoracic Oncology, 8(3), 369–372.PubMedCentralPubMedCrossRef
74.
Besse, B., Leighl, N., Bennouna, J., Papadimitrakopoulou, V. A., Blais, N., Traynor, A. M., Soria, J. C., Gogov, S., Miller, N., Jehl, V., & Johnson, B. E. (2014). Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Annals of Oncology, 25(2), 409–415.PubMedCrossRef
75.
Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T. E., Damyanov, D., Stella, P., Ganchev, H., Pover, G., Morris, C., & Tzekova, V. (2010). A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. Journal of Thoracic Oncology, 5(10), 1630–1636.PubMedCrossRef
76.
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., Smith, I., & Crinò, L. (2013). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncology, 14(1), 38–47.PubMedCrossRef
77.
Infante, J. R., Papadopoulos, K. P., Bendell, J. C., Patnaik, A., Burris, H. A., Rasco, D., Jones, S. F., Smith, L., Cox, D. S., Durante, M., Bellew, K. M., Park, J. J., Le, N. T., & Tolcher, A. W. (2013). A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer, 49(9), 2077–2085.PubMedCrossRef
78.
Blumenschein, G. R., Jr., Smit, E. F., Planchard, D., Kim, D. W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M. J., Hanna, N. H., Kim, J. H., Mazieres, J., Kim, S. W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F. S., & Jänne, P. A. (2015). A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Annals of Oncology, 26(5), 894–901.PubMedCrossRef
79.
Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H., Spano, J. P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., Pacey, S., Venturi, M., Kraeber-Bodéré, F., Tessier, J. J., Eberhardt, W. E., Paques, M., Guarin, E., Meresse, V., & Soria, J. C. (2014). Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clinical Cancer Research, 20(16), 4251–4261.PubMedCrossRef
80.
Honda, K., Yamamoto, N., Nokihara, H., Tamura, Y., Asahina, H., Yamada, Y., Suzuki, S., Yamazaki, N., Ogita, Y., & Tamura, T. (2013). Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 72(3), 577–584.PubMedCrossRef
Metadata
Title
Allosteric therapies for lung cancer
Authors
Ye Ling
Meiling Jing
Xiang-dong Wang
Publication date
01-06-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9567-z

Other articles of this Issue 2/2015

Cancer and Metastasis Reviews 2/2015 Go to the issue

OriginalPaper

Association of chromosome 19 to lung cancer genotypes and phenotypes

Erratum

Erratum to: Association of chromosome 19 to lung cancer genotypes and phenotypes

Announcement

Biographies

OriginalPaper

Targeting roles of inflammatory microenvironment in lung cancer and metastasis

OriginalPaper

Five critical elements to ensure the precision medicine

OriginalPaper

Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits